doravirine

Doravirine is a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) developed by Merck for the treatment of HIV-1 infection. It functions by binding allosterically to the HIV-1 reverse transcriptase enzyme, thereby inhibiting the conversion of viral RNA into DNA. Unlike earlier NNRTIs, doravirine maintains significant activity against common NNRTI-resistant mutations such as K103N, Y181C, and G190A. It is FDA-approved as a standalone 100 mg tablet (Pifeltro) and as part of a fixed-dose combination (Delstrigo). The University of North Carolina, Chapel Hill is currently conducting a Phase 1 pharmacokinetic study (NCT04900974) to evaluate the appropriate dosing of doravirine in pregnant women with HIV during the second and third trimesters and the postpartum period.

Brand names

Pifeltro

Other names

doravirine